XML 16 R2.htm IDEA: XBRL DOCUMENT v3.5.0.2
Consolidated Balance Sheets - USD ($)
Jun. 30, 2016
Dec. 31, 2015
Current Assets    
Cash and cash equivalents $ 7,115,392 $ 4,939,955
Investments, held to maturity (net) 6,689,643
Prepaid expenses and other current assets 440,016 869,158
Total Current Assets 7,555,408 12,498,756
Property and Equipment, net 423,681 445,733
Other Assets    
Restricted cash 100,039 101,151
Deposits 69,798 69,798
Related party receivable 85,017 58,017
Deferred financing costs 21,600
Total Other Assets 254,854 250,566
Total Assets 8,233,943 13,195,055
Current Liabilities    
Accounts payable 478,104 1,980,676
Accrued expenses and other payables 1,080,176 1,846,907
Current portion of long term debt 3,133,958 3,133,958
Total Current Liabilities 4,692,238 6,961,541
Long Term Liabilities    
Long term debt, net of discount and current portion 2,027,399 3,589,036
Other long term liabilities 396,765 149,748
Total Liabilities 7,116,402 10,700,325
Commitments and Contingencies
Stockholders' Equity    
Common stock, $0.0002 par value; 50,000,000 shares authorized, 17,524,641 and 8,424,641 shares issued and outstanding at June 30, 2016 (unaudited) and December 31, 2015, respectively 3,186 1,366
Additional paid in capital 54,981,269 48,566,451
Accumulated deficit (51,915,528) (44,430,703)
Accumulated other comprehensive loss (113,158) (86,584)
Total Stockholders' Equity - Heat Biologics, Inc. 2,955,769 4,050,530
Non-Controlling Interest (1,838,228) (1,555,800)
Total Stockholders' Equity 1,117,541 2,494,730
Total Liabilities and Stockholders' Equity $ 8,233,943 $ 13,195,055